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Introduction
Liver transplantation has become the standard of care for the treatment of a variety of liver
diseases that in the past would have resulted in an early death. According to the United Network
for Organ Sharing (UNOS) there are currently 14,433 candidates waiting for a liver transplant in
the United States. A total of 7,841 liver transplants were performed in the United States in
2016[1]. Despite increased education regarding organ donation and advances in patient
management, there continues to be a gap in the supply and demand of organs for transplant. Due
to this scarce resource, pre and post- transplant patient management remains a key focus in
achieving optimal outcomes. Transplant medicine is a highly complex, specialized field,
requiring specialized knowledge and management of the patient in the pre-transplant phase and
the early post -transplant period. Patients requiring a liver transplant often are managed in the
outpatient setting but can require intensive care placement for acute liver failure or
decompensated end stage liver disease (ESLD). Critical care nurses play a role in the care of
these patients. The best patient outcomes occur when expertise and experience coincide[2]. The
purpose of this article is to provide critical care nurses with an overview of liver disease and
transplantation for adult patients with a diagnosis of liver failure.

(S)Overview of Liver Function

The liver is the largest internal organ in the human body. Weighing an average of 3 pounds in the
average adult, it performs more than 500 critical functions (REF). At any time, it holds one
quarter of the body’s blood supply, and filters 1.4 liters of blood per minute and is responsible
for 25% of the cardiac output. The portal vein supplies 75% of the liver’s blood flow, and the
remaining 25% of blood supply to the liver comes from the hepatic artery. Substances
transported tothe liver may be metabolized, stored, modified, or detoxified and then released
into the circulation or intestine to be excreted. The liver plays a vital role in fat metabolism,
gluconeogenesis, and the metabolism of carbohydrates. It is an important metabolizer of
proteins, converting amino acids from foods to produce energy, fats, or carbohydrates. The byproduct of this energy conversion is ammonia, which the liver converts to urea which is released
into the blood, transported to the kidneys, and finally removed from the body in urine. The liver
synthesizes several clotting factors, II, VII, IX, X, as well as factor V and factor XI (Northrup,
Caldwell). It plays a primary role in gluconeogenesis and regulates blood glucose levels and
produces approximately one liter of bile per day. Bile is vital for the absorption of fat-soluble
vitamins and elimination of toxic substances.
The liver is the primary site for metabolism of medications through enzymes within the
Cytochrome P450 (CYP 450) pathways. Drugs that affect these pathways are referred to as either
inhibitors or inducers; those that cause increased concentrations of other drugs that utilize this
pathway are inhibitors and can lead to subtherapeutic drug levels. Conversely, drugs that cause
decreased concentrations are inducers and can cause toxic drug levels to occur. J Adv Pract
Oncol. 2013 Jul-Aug; 4(4): 263–268.
Published online 2013 Jul 1. Basic Review of the Cytochrome P450 System Anne M
McDonnell, Cathyyen H. Dang. This pathway can upregulate or downregulate the

Management of renal failure in end-stage liver disease: A critical appraisal. Liver
Transplantation Volume 22, Issue 12December 2016 Pages 1710–1719
Xingxing S. Cheng,Jane C. Tan,W. Ray Kim Hypotension is a key risk factor. As seen in Fig.
2, a simplified representation of the work done by Stadlbauer et al.,[21] the relationship
between renal blood flow and mean arterial pressure is increasingly altered as the cirrhosis
stage worsens, a phenomenon known as loss of autoregulation. In a patient with advanced
cirrhosis, who is frequently hypotensive at baseline, his or her kidneys “live” on the steep
part of the curve, therefore any slight alteration in volume status or systemic vascular
resistance with even a minor hypotensive effect can lead to a drastic reduction in renal blood
flow and, subsequently, GFR.

Liver disease, especially cirrhosis, is characterized by reduced synthesis of the procoagulant
proteins II, VII, IX, X, as well as factor V and factor XI Coagulation in Liver Disease: A
Guide for the Clinician Patrick G. Northup, Stephen H. CaldwellClinical Gastroenterology
and Hepatology Volume 11, Issue 9, September 2013, Pages 1064-1074
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-Gluconeogenesis
-Fat, protein, carbohydrate metabolism
-Produces bile
-Synthesizes albumin
-Activation of Vitamin D
-Converts fats to ketones
- Stores fat soluble vitamins, B 12, trace
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-CYP 450 pathways
Produces clotting factors II, VII, IX, X,
Factor V, XI
Detoxifies blood

Coagulation
Immunologic

Converts ammonia to urea
Endocrine

Produces
angiotensinogen,
somatomedin
Hemolysis of red blood cells

secretes

(S)Causes of Liver Failure
Liver failure is often categorized as acute or chronic end stage liver disease, resulting in the need
for a liver transplant to prolong the patient’s life. Inflammation: early stage of liver disease, shows
it is fighting off infections or heal injury.
Fibrosis: inflammation untreated liver scars. Scar tissue is unable to do the work that healthy tissue
can do. At this stage, the scar tissue can be repaired and liver can heal and have improved to normal
function.
Cirrhosis: left untreated, significant fibrosis leads to scarring that cannot be reversed. Cirrhosis can
lead to a variety of chronic liver complications, such as liver cancer.
DIAGNOSES SEE TABLE FROM OFFICE

(S)Indications for Liver Transplant
The need for liver transplant is considered when a patient with cirrhosis has signs and symptoms
of hepatic decompensation in spite of the use of maximized medical therapies (Martin et al 2014
AASLD Eval for Liver tran in adults 2013). The most common indicators for transplant are
variceal bleeding from the esophagus and/or stomach, bleeding due to portal hypertension,

significant coagulopathy, hepatic encephalopathy, spontaneous bacterial peritonitis, and severe
and persistent ascites. SEE TABLE 1 below from Martin, et al, AASLD Guidelines 2013. Once
hepatic decompensation develops, the patient with cirrhosis can quickly decompensate since
additional complications such as sepsis, hepotorenal syndrome, and hepatic carcinoma are likely
to hasten mortality.
Acute Hepatic Failure
In the Intensive Care Unit (ICU) patients awaiting liver transplant typically have been
admitted in acute or “fulminant” hepatic failure (AHF). This is defined as “hepatic
encephalopathy within 8 weeks from the appearance of clinical evidence of hepatic failure
without a history of previous liver disease”. (AASLD/UNOS). The clinical presentation typically
includes hepatic dysfunction, significant coagulopathy, and may include hepatic encephalopathy
(HE). If left untreated HE may progress to cerebral edema, ultimately leading to multi-organ
system failure and death occurring in up to half the cases (Acute Liver Failure William Bernal,
M.D., and Julia Wendon, M.B., Ch.B. N Engl J Med 2013; 369:2525-2534December 26,
2013DOI: 10.1056/NEJMra1208937). Although the etiology of acute hepatic failure can be
due to a variety of factors in the United States the most common cause is due to drug-induced
injury. Acetaminophen and certain anticonvulsants are well-known for causing AHF, as well as
undiagnosed autoimmune disease and viruses.
Signs and symptoms of acute hepatic failure
•
•
•
•
•
•
•

Encephalopathy
Cerebral edema and/or associated signs of ICP
Jaundice
Ascites
Right upper quadrant tenderness
Change in liver span
Hematemesis or melena

•

Hypotension and tachycardia

The development of cerebral edema is a major cause of morbidity and mortality in
patients with acute liver failure. Studies have demonstrated that an ammonia level
f >100 lM on admission represent an independent risk factor for the development
of high-grade hepatic encephalopathy, and a level of >200 lM predicts ICH (AASLD
Lee,Stravitz, Larson March 2012 Hepatology)

TABLE 1 ACUTE LIVER FAILURE COMPLICATIONS OF CIRRHOSIS:
•
Ascites
•
Chronic gastrointestinal blood loss due to portal hypertensive gastropathy
•
Encephalopathy
•
Liver cancer
•
Refractory variceal hemorrhage
•
Synthetic dysfunction
Liver Transplant Evaluation
Patients with acute fulminant liver failure (AFLF) or end stage liver disease (ESLD) experience
the sequelae of liver disease, often requiring admission to the intensive care unit ( ICU ) for
medical management. Chronic and acute liver failure patients are considered candidates for liver
transplantation, now a treatment modality to decrease patient death. Intensive, supportive critical
care patient management and liver transplantation provides an opportunity for patient survival
for the majority of patients with acute fulminant liver failure[3]. The one year survival rate for
patients with a primary (first) liver transplant is 91.8%.[1]. Currently there are approximately
170 transplant centers in the United States[1]. Patients referred for transplantation will be seen
and evaluated at a transplant center by the transplant team. The ICU nurse can work with the

transplant team to provide psychological support and education to the patient and family during
the evaluation process.

Transplant centers provide the expertise of a multidisciplinary transplant team approach to the
evaluation process. The patient undergoes both physical and psychological testing to determine
readiness for transplantation and the required long term care post- transplant care. The transplant
evaluation is described as a 3-fold process with goals of establishing a diagnosis of ESLD;
excluding any absolute or relative contraindications to transplant; and determining the suitability
and degree of patient illness to better allocate resources and optimize survival[4]. The transplant
evaluation process may vary from center to center with patient specific diagnostic testing being
required. Common components of the transplant work-up include blood tests, diagnostic
imaging and testing, psychological evaluation and consultation with other specialist depending
on the patient’s condition. Blood testing includes: liver function tests, PT/INR, a
comprehensive metabolic panel, CBC with differential, blood type and screen, hepatitis
screening (A, B, C), virology screening for cytomegalovirus (CMV), herpes simplex virus(HSV),
Epstein-Barr virus(EBV) and HIV, tumor markers, including Alpha-fetoprotein(AFP), atrial
blood gases(ABGs). Patients may require toxicology testing for alcohol and drugs pending the
etiology of liver disease. Imaging studies include: chest radiography, duplex ultrasonography,
abdominal CT scanning, CT scanning of the chest and pelvis or magnetic resonance angiography
(MRI) if indicated. Imaging studies are required to detect malignancies in the pre-transplant
patient. Pre transplant cirrhotic patients with hepatocellular carcinoma will requiring serial
scanning to monitor tumor size and to determine treatment modalities pre transplant and tumor
listing criteria. Additional tests to exclude malignancies may include: mammography and PAP

testing for women and PSA for men. The patient undergoing transplant evaluation will also
require testing to evaluate cardiac and pulmonary function. Testing may include: stress thallium
scanning, coronary angiography and echocardiography, electrocardiography and pulmonary
function tests. Upper and lower GI endoscopies to evaluate for esophageal or gastric varices and
to exclude malignancies of the GI tract may be required. Patients may require paracentesis for
treatment of ascites and to rule out spontaneous bacterial peritonitis (SBP). Consultations and
medical clearances are usually obtained from the following specialty services: cardiopulmonary,
psychiatry and social work. If indicated, nephrology, infectious disease and dental work-ups
may be needed before the patient can be listed. Financial clearance is always obtained prior to
listing a patient for transplant.

Contraindications for liver transplant have become fewer over recent years. Transplant centers
may vary in defining the relative contraindications specific to certain diseases or psychosocial
conditions. Many centers mandate abstinence from alcohol, drug and nicotine use for 6 months
prior to transplantation with center specific protocols for screening. A positive screen can render
the patient inactive on the transplant list and even lead to delisting.

Absolute or relative

contraindications to transplant are listed in table 1.
TABLE 1
Absolute and Relative Contraindications for Liver Transplantation
Absolute Contraindications
Brain Death or acute liver failure with intracranial
pressure greater than 50 mm Hg or cerebral
perfusion pressure less than 40 mm Hg
Active alcohol abuse or drug use
Extrahepatic malignancy
Uncontrolled sepsis

Relative Contraindications
Advanced age(center specific)

Severe malnutrition
Morbid obesity
HIV(center specific)

Certain medical conditions: advanced cardiac or
pulmonary disease; acquired immune deficiency
syndrome
Anatomical abnormality or thrombosis of the
superior mesenteric vein and portal vein which
would preclude transplantation
Persistent noncompliance (center specific)
5, 6

Multi organ failure
Cholangiocarcinoma(center specific)
Psychosocial conditions: dx of mental illness,
non-compliance, lack of psychosocial support

Organ Allocation and Listing for Transplant
The Organ Procurement and Transplant Network (OPTN) and the United Network for Organ
Sharing (UNOS) are responsible for managing the United States organ allocation[7]. Medical
professionals, transplant recipients and donor families provide input in the national policies
governing transplant, following the goals of the OPTN to increase numbers of transplants, provide
equity to transplant access, improve waitlist, living donor and transplant recipient outcomes,
promote safety for living donors and transplant recipients and promote efficient management of
the OPTN [1].
Patient disease and illness severity plays a key role in organ allocation and patient listing for
transplant. Scoring systems are specified according to age with The Model for End-Stage Liver
Disease (MELD) used for patients 12 years and older. The MELD calculator provides a scoring
system to determine how urgently a patient will need a liver transplant within the next three
months [1]. The MELD calculates a patient’s score based on the following laboratory tests:
serum creatinine (mg/dl), bilirubin(mg/dl), INR, and serum sodium (mEq/L). The serum
sodium, especially a low sodium level, is variable associated with mortality, independent of the
MELD score and has recently been added to the MELD calculator[8]. Kidney function is also
assessed through the question: has the patient had dialysis twice within the last week, or 24 hours

of CVVHD? If yes, the creatinine value is automatically registered at 4 mg/dl. Often patients in
the ICU setting are requiring dialysis or CVVHD. The MELD calculation determines organ
allocation based on the patient’s score and geographic location. Scores range from 6 to 40 with a
higher score indicating a sicker patient. An exception to this rule are patients that receive MELD
exception points based on certain diagnoses such as hepatocellular carcinoma and
portopulmonary hypertension to account for a higher waitlist mortality not reflected in the
MELD score [9].
In 2013 the Share 35 policy was approved by UNOS mandating regional sharing of livers
throughout 11 UNOS regions for patients with a MELD of 35 or greater. The Share 15 policy
provides patients with a MELD of 15 or greater offers from the local organ procurement
organization (OPO) first and then regionally Critically ill patients in the ICU setting with a life
expectancy of seven days or less qualify for a status IA on the UNOS list.
Status IA organ offers can be from the local, regional or national UNOS list. If the patient’s
condition worsens and the patient becomes temporarily too unstable to undergo a liver transplant,
the patient’s status is changed to a status 7. Status 7 makes the patient inactive on the transplant
list until stabilization is achieved and the status is updated. Status The patient’s blood type and
size are also required for UNOS listing with organ acceptance dependent on donor-patient size
similarity and blood type compatibility.

Critical care nurses are involved with the ICU team in providing patient stabilization and
supportive care to prevent further complications until an organ becomes available. Measures to
manage the acutely ill pre-transplant patient includes seizure prophylaxis and surveillance;
treatment of cerebral edema and inter cranial hypertension; management of encephalopathy and

coagulopathy; mechanical ventilation; treatment of circulatory dysfunction; infection
surveillance and treatment; nutritional management; and management of fluids, electrolytes and
glucose [11]. When a suitable organ is found for the patient, the liver transplant is performed
and the patient returns to the ICU for post- transplant management. It is important for ICU
nurses to be familiar with potential complications that can occur, often requiring immediate
intervention. Early Post-Transplant Complications
Complications occurring post liver transplant can be categorized into early and late
complications. For the purpose of this article, focus will be on the early post- transplant
complications. Use of extended criteria donors (ECD) can increase the risk of less than optimal
patient outcomes, including early complications. Donor variables known to affect patient
outcomes include increased age, long hospitalization, extended warm or cold ischemic times and
donor liver steatosis, leading to reperfusion syndrome, ischemia and graft dysfunction[12, 7].
Primary Graft non-function(PGNF)
Complete graft failure immediately post-transplant without a definitive cause has been defined as
primary non-function. This type of liver injury can result in severe liver dysfunction with
elevation in liver enzymes immediately post-transplant, secondary organ damage due to the liver
dysfunction, biliary strictures and even re-transplant. Patients exhibit symptoms of comma,
coagulopathy, oliguria, hypoglycemia and marked elevation in liver function tests with
transaminases often greater than 5000 U/L[7]. The critical care nurse must be aware of these signs
and symptoms of liver dysfunction and alert the transplant team.
Early Acute Cellular Rejection
Early acute cellular rejection usually occurs within the first 90 days post liver transplant while
chronic rejection can occur later post- transplant, and is usually a result of low

immunosuppression levels. Acute cellular rejection is usually reversible but chronic rejection
can affect long term graft and patient survival. Symptoms of acute rejection can include elevated
LFTs (serum aminotransferases, alkaline phosphatase, gamma-glutamyl transpeptidase (GGT),
and bilirubin levels), fever, abdominal pain and malaise. The gold standard to diagnose
rejection is liver biopsy, percutaneous or transjugular.

Treatment for rejection includes high

dose corticosteroids, and an increase in immunosuppressant dosing or adding a second agent.
Patients transplanted for HCV may be treated without the addition of steroids due to the impact
on HCV progression. HCV and rejection have similar histological markers, often making
diagnosis difficult to differentiate. Patients transplanted with a diagnosis of autoimmune
hepatitis may require a more aggressive approach to the treatment of rejection, including high
dose steroids. It is important to differentiate rejection from infection in the early post liver
transplant patient to ensure appropriate treatment.

Vascular Complications
Hepatic Artery Thrombosis
Hepatic Artery Thrombosis (HAT) has been estimated to occur in 4-12% of adult liver
transplants with causes including hepatic artery narrowing, kinking or a mismatch with the
donor- recipient vessels[13]. Hepatic artery thrombosis is diagnosed through Doppler
ultrasonography. Re-transplantation is indicated if blood flow cannot be restored to the
transplanted graft.
Portal Vein Thrombosis
Portal Vein Thrombosis(PVT) occurs in approximately 1-13% of liver transplant recipients and
can be the result of technical problems during the time of surgery, thrombus formation, or a

hypercoagulable state [13]. A PVT can be diagnoses through ultrasonography showing an
increase in velocity within the portal vein; CT scanning; an MRI or magnetic resonance
venography (MRV). Treatment may include a thrombectomy, transjugular intrahepatic
portosystemic shunt (TIPS) or re-transplant.
Biliary Complications
Liver transplantation requires biliary reconstruction, connecting the common hepatic duct of the
donor to the native bile duct of the recipient(choledocho-choledochostomy) or connection of the
donor common bile duct to a portion of the recipient’s jejunum ( Roux-en-Y
choledochojejunostomy). The type of biliary reconstruction is determined by surgeon
preference, underlying liver disease, donor and recipient bile duct size or previous surgeries [14].
Use of a temporary biliary stent for an end-to-end biliary connection is also determined by
transplant surgeon preference. Depending on stent placement technique, the stent may be
passed through the GI track or require removal through an endoscopic retrograde
cholangiopancreatography (ERCP) around three month post- transplant. The stent is radiopaque
with placement or migration can be confirmed on abdominal x-ray.
Approximately 13-19% of adults receiving a deceased donor liver transplant can have biliary
complications[13] Biliary complications include biliary strictures and bile leaks.
Biliary Leaks and Strictures
The ICU nurse will be more concerned about biliary leaks in the immediate post operative
period. Early biliary leaks are usually a result of technical issues, including lack of perfusion
from the hepatic artery and occur at the biliary anastomosis. The patient may present with fever,
abdominal pain and elevation in liver function tests. Imaging may include an US, cholangiogram
or MRCP, showing peritonitis or fluid collections. An endoscopic retrograde cholangiography

(ERC) usually is performed for patients with a choledocho-choledochostomy and requiring
biliary stent placement. Repeat LFTs are usually performed 1-2 weeks post-procedure.
Depending on the type of stent (plastic or metal), the stent will be removed or exchanged within
three to six months. Biliary strictures can be at the site of the anastomosis, usually occurring
within the first 6- 12 months post- transplant.Bilomas
A biloma can occur from biliary necrosis due to hepatic artery thrombosis. The biloma can be
perihepatic or within the hepatic parenchyma. Treatment may include antibiotics, percutaneous
drainage or surgical repair.

Early Acute Cellular Rejection
Early acute cellular rejection usually occurs within the first 90 days post liver transplant while
chronic rejection can occur later post- transplant, and is usually a result of low
immunosuppression levels. Acute cellular rejection is usually reversible but chronic rejection
can affect long term graft and patient survival. Symptoms of acute rejection can include elevated
LFTs (serum aminotransferases, alkaline phosphatase, gamma-glutamyl transpeptidase (GGT),
and bilirubin levels), fever, abdominal pain and malaise. The gold standard to diagnose
rejection is liver biopsy, percutaneous or transjugular. The three histological features indicating
acute cellular rejection are mixed inflammatory infiltrate in the portal triad; destructive or
nondestructive nonsuppurative cholangitis involving the interlobular bile duct epithelium and
endotheliitis[16]. Treatment for rejection includes high dose corticosteroids, and an increase in
immunosuppressant dosing or adding a second agent. Patients transplanted for HCV may be
treated without the addition of steroids due to the impact on HCV progression. HCV and
rejection have similar histological markers, often making diagnosis difficult to differentiate.

Patients transplanted with a diagnosis of autoimmune hepatitis may require a more aggressive
approach to the treatment of rejection, including high dose steroids. It is important to
differentiate rejection from infection in the early post liver transplant patient to ensure
appropriate treatment.
Infection
Post- transplant infections can be classified into three periods: transplant to one month; the
second through sixth month and greater than six months. In the early post- transplant period,
patients are at greater risk of infections, especially opportunistic, due to the high levels of
immunosuppression. Bacterial, nosocomial infections are prevalent in the early hospitalized
period due to central vascular access sites, indwelling catheters and drainage tubes, surgical
complications, wound infections, and prolonged mechanical ventilation. C. Difficle infections
are common during the hospitalization due to immunosuppression and antibiotic treatment. .
While donors are screened for all types of infections prior to transplant, if unexplained symptoms
of infection occur, consider the possibility of a donor infection. Infection prophylaxis is started
during the hospitalization with length of treatment per transplant center protocols. Refer to Table
2.
TABLE 2
Prophylaxis During the Early Post Transplant Period
Infection

Prophylaxis

Pneumocystis jirovecii (formerly P. carinii)
pneumonia (PCP)
Cytomegalovirus (CMV)
Candida
16

Trimethoprim-sulfamethoxazole 6-12
months.
If allergic use Pentamidine, Dapsone,
Atovaquone
Ganciclovir IV or Valganciclovir oral
Antifungal such as Fluconazole, Mycelex,
Nystatin

Renal Dysfunction
Hypovolemia during and early post operatively along with high levels of immunosuppressant
agents with known renal toxicity can cause worsening of kidney function. It is important for the
ICU nurse to monitor the patient’s renal function and urine output, observing for worsening
function, indicating the need for dialysis. Immunosuppression will need to be modified in the
picture of worsening kidney function due to the nephrotoxic effects of the calcineurin inhibitors (
Cyclosporine and Tacrolimus).
Additional Complications
Post-operative nursing management includes patient assessment for bleeding, wound infection or
dehiscence and neurological changes. Coagulopathy and encephalopathy should improve posttransplant as liver function normalizes. Careful monitoring of the patient’s mental status is
required with any subtle change noted to the transplant team. High immunosuppression levels or
electrolyte imbalances can cause seizure activity.
Immunosuppression
Common immunosuppressant agents are listed in Table 3. Transplant centers have specific
protocols for immunosuppression dosing, monitoring and therapeutic drug levels related to post
transplant time periods.
TABLE 3
Immunosuppressive Agents
Drug

Class

Cyclosporine

calcineurin inhibitor(CNI)

Tacrolimus
Sirolimus or Everolimus

calcineurin inhibitor (CNI)

Mycophenolate mofitel

Inhibitor of mechanistic target of Rapamycin
(MTOR)
Inhibitor of mechanistic target of Rapamycin
(MTOR)

Azathioprine
Prednisone

Inhibitor of mechanistic target of Rapamycin
(MTOR)
corticosteroid

Long Term Follow Up

Long term management of the liver transplant patient becomes a joint venture between the
primary care provider in the local community and the transplant center. Co-management can
ensure the best patient outcomes. Transplant centers have specific protocols for the timing of
transplant labs, including immunosuppression levels, protocol liver biopsies, and specific
diagnostic testing based on the patient’s diagnosis at time of transplant. Primary care providers
are involved with providing preventative care and managing complications of long term
immunosuppression. Transplant patients must be monitored and treated for renal insufficiency,
hypertension, hyperglycemia, malignancies and disease recurrence (HCV
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